SCYX — Scynexis Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$5.29
+$0.12 (+2.30%)
Scynexis Inc (SCYX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by David Gonzalez Angulo M.D., based in 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548, with about 18 employees. SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Latest reported SCYX revenue for 2025-09-30 was $334.0K. Net income was -$20.9M. Revenue was down 75.5% from 2025-06-30 to 2025-09-30. SCYX currently screens at market cap $37.7M.
Use this SCYX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SCYX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SCYX SEC filings page. Lician reads the product cache first so this HTML stays unique to Scynexis Inc even when a live quote feed is slow.
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Key Statistics
Market Cap
$37.74M
Volume
215,785
Previous Close
$5.19
Day Range
$5.10 – $6.09
P/B Ratio
0.92
EPS
-$0.44
Revenue
$3.75M
Net Income
-$21.29M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-97.3%
Profit Margin
-568.3%
Employees
18
SCYX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $3.75M | $140.14M | $5.09M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.29M | $67.04M | -$62.81M |
| EPS (Diluted) | -$0.44 | $1.39 | -$1.47 |
Total Assets
$90.64M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$16.05M
Operating Cash Flow
-$24.01M
Free Cash Flow
$0.00
Scynexis Inc Company Information
- CEO, President & Director
- David Gonzalez Angulo M.D.
- Headquarters
- 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
- Website
- www.scynexis.com
- Phone
- 201 884 5485
- IPO / Founded
- 2014-05-02
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic